铁死亡诱导联合髓源性抑制细胞阻断使肝脏原发肿瘤和转移瘤对免疫检查点阻断敏感
该研究在小鼠肝细胞癌和结直肠癌模型中遗传修饰GPx4以探究铁死亡对肿瘤免疫微环境的影响。肝细胞GPx4缺失不抑制肝肿瘤发生,而通过CXCL10依赖的细胞毒性CD8+ T细胞浸润、PD-L1上调和HMGB1介导的MDSC浸润形成肿瘤抑制性免疫反应。阻断PD-1或HMGB1可延长Gpx4缺失肝肿瘤小鼠生存;铁死亡诱导剂withaferin A、CXCR2抑制剂SB225002和α-PD-1三联方案改善野生型肝肿瘤小鼠生存,但不影响皮下结直肠癌类器官生长而减少其肝转移。
要点
- 肝细胞GPx4缺失不抑制肝肿瘤发生,而是诱导CXCL10依赖的CD8+ T细胞浸润。
- PD-L1上调和HMGB1介导的MDSC浸润抵消了铁死亡诱导的抗肿瘤免疫反应。
- withaferin A、SB225002和α-PD-1三联方案改善野生型肝肿瘤小鼠生存并减少肝转移。
核心结论
- 铁死亡诱导的免疫反应具有背景特异性,可用于治疗原发性肝肿瘤和肝转移。
研究设计与样本
- 在小鼠肝细胞癌和结直肠癌模型中遗传修饰GPx4,分析铁死亡对肿瘤细胞和免疫肿瘤微环境的影响。
- findings served as foundation for identifying additional targets for combination therapy with ferroptotic inducer in HCC and liver metastasis.
主要发现
- 肝细胞限制性GPx4缺失不抑制肝细胞肿瘤发生。
- GPx4相关铁死亡性肝细胞死亡引起CXCL10依赖的细胞毒性CD8+ T细胞浸润,并被肿瘤细胞PD-L1上调和HMGB1介导的MDSC浸润所抵消。
- 阻断PD-1或HMGB1可释放T细胞活化并延长Gpx4缺失肝肿瘤小鼠生存。
- withaferin A、SB225002和α-PD-1三联方案大幅改善野生型肝肿瘤小鼠生存。
- 相同三联方案不影响皮下生长的结直肠癌类器官肿瘤生长,但减少其肝转移生长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Investigating the effect of ferroptosis in the tumour microenvironment to identify combinatory therapy for liver cancer treatment. DESIGN: Glutathione peroxidase 4 (GPx4), which is considered the master regulator of ferroptosis, was genetically altered in murine models for hepatocellular carcinoma (HCC) and colorectal cancer (CRC) to analyse the effect of ferroptosis on tumour cells and the immune tumour microenvironment. The findings served as foundation for the identification of additional targets for combine therapy with ferroptotic inducer in the treatment of HCC and liver metastasis. RESULTS: Surprisingly, hepatocyte-restricted GPx4 loss does not suppress hepatocellular tumourigenesis. Instead, GPx4-associated ferroptotic hepatocyte death causes a tumour suppressive immune response characterised by a CXCL10-dependent infiltration of cytotoxic CD8+ T cells that is counterbalanced by PD-L1 upregulation on tumour cells as well as by a marked HMGB1-mediated myeloid derived suppressor cell (MDSC) infiltration. Blocking PD-1 or HMGB1 unleashes T cell activation and prolongs survival of mice with Gpx4-deficient liver tumours. A triple combination of the ferroptosis inducing natural compound withaferin A, the CXCR2 inhibitor SB225002 and α-PD-1 greatly improves survival of wild-type mice with liver tumours. In contrast, the same combination does not affect tumour growth of subcutaneously grown CRC organoids, while it decreases their metastatic growth in liver. CONCLUSION: Our data highlight a context-specific ferroptosis-induced immune response that could be therapeutically exploited for the treatment of primary liver tumours and liver metastases.
引用
- Conche C, Finkelmeier F, Pešić M, et al. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023. PMID: 36707233. doi:10.1136/gutjnl-2022-327909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。